Neuphoria Therapeutics (NEUP) Tax Provisions (2023 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Tax Provisions of -$34793.0 for Q1 2026, up 57.14% year-over-year from -$22140.8 in Q1 2025, and little changed quarter-over-quarter from -$34794.0 in Q4 2025.
Neuphoria Therapeutics (NEUP) Tax Provisions (2023 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Tax Provisions for 4 consecutive years, with -$34793.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Tax Provisions rose 57.14% year-over-year to -$34793.0; the TTM figure through Mar 2026 stood at $97445.0 (up 116.0% YoY), while the FY2025 annual figure was $61.0, up 100.01% from the prior year.
- Tax Provisions held at -$34793.0 in Q1 2026 per NEUP's latest filing, from -$34794.0 in the prior quarter.
- Across five years, Tax Provisions topped out at $201825.0 in Q2 2025 and bottomed at -$407093.0 in Q2 2024.
- Historically, Tax Provisions has averaged -$51328.7 across 4 years, with a median of -$34793.0 in 2023.
- On a YoY basis, Tax Provisions climbed as much as 149.58% in 2025 and fell as far as 595.55% in 2025.
- Neuphoria Therapeutics' Tax Provisions stood at -$34794.0 in 2023, then soared by 133.36% to $11609.0 in 2024, then tumbled by 399.72% to -$34794.0 in 2025, then gained by 0.0% to -$34793.0 in 2026.
- Business Quant data shows NEUP's Tax Provisions at -$34793.0 in Q1 2026, -$34794.0 in Q4 2025, and -$34793.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.09 Bn | 131.23 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.66 Bn | 77.66 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 64.86 Bn | 59.67 Bn | 1.37 Bn | 59.00 Mn |
| 4 | Moderna | 58.07 Bn | 52.93 Bn | 52.00 Mn | 15.00 Mn |
| 5 | BeOne Medicines | 41.87 Bn | 36.77 Bn | 1.53 Bn | 75.45 Mn |
| 6 | Alnylam Pharmaceuticals | 31.45 Bn | 28.15 Bn | 992.69 Mn | 13.31 Mn |
| 7 | BioNTech SE | 27.90 Bn | 9.51 Bn | 668.28 Mn | -90.33 Mn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 1.90 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | - |
| 10 | Neuphoria Therapeutics | 21.28 Mn | 1.84 Mn | - | -34,793.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34,793.00 |
| Dec 31, 2025 | -34,794.00 |
| Sep 30, 2025 | -34,793.00 |
| Jun 30, 2025 | 201,825.00 |
| Mar 31, 2025 | -81,186.00 |
| Dec 31, 2024 | 11,609.00 |
| Sep 30, 2024 | -132,187.00 |
| Jun 30, 2024 | -407,093.00 |
| Mar 31, 2024 | 16,383.00 |
| Dec 31, 2023 | -34,794.00 |
| Sep 30, 2023 | -34,793.00 |